Literature DB >> 20457587

Considerations for clinical trial design and data analyses of thorough QT studies using drug-drug interaction.

Hao Zhu1, Yaning Wang, Jogarao V Gobburu, Christine E Garnett.   

Abstract

Mesh：

Year:  2010        PMID： 20457587     DOI： 10.1177/0091270009358710

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  8 in total

Review 1.  Quantitative clinical pharmacology is transforming drug regulation.

Authors:  Carl C Peck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-10-27       Impact factor: 2.745

2.  Detection of QTc effects in small studies--implications for replacing the thorough QT study.

Authors:  Georg Ferber; Meijian Zhou; Borje Darpo
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-11-04       Impact factor: 1.468

3.  The effects of active metabolites on parameter estimation in linear mixed effect models of concentration-QT analyses.

Authors:  Peter L Bonate
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-01-04       Impact factor: 2.745

4.  Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.

Authors:  Borje Darpo; Georg Ferber; Meijian Zhou; Mark Sumeray; Philip Sager
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-30       Impact factor: 1.468

Review 5.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

6.  Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria.

Authors:  Borje Darpo; Georg Ferber; Peter Siegl; Bart Laurijssens; Fiona Macintyre; Stephen Toovey; Stephan Duparc
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

7.  Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.

Authors:  Justin Hoffman; Jayeta Chakrabarti; Anna Plotka; Adriana Milillo Naraine; David Kanamori; Rebecca Moroose; Linh Nguyen; Diane Wang; Zev A Wainberg
Journal:  Anticancer Drugs       Date:  2019-06       Impact factor: 2.248

8.  Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.

Authors:  Philip T Sager; Barbara Balser; Julie Wolfson; Jean Nichols; Richard Pilot; Suzanne Jones; Howard A Burris
Journal:  Cancer Med       Date:  2015-04-27       Impact factor: 4.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.